Less Mental Decline With Darolutamide vs Enzalutamide in PC

Published Date: 22 May 2026

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Read Full News

Latest News

Race, Geography Linked to Gaps in Prostate Cancer Care

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

AI-Driven Biomarker Predicts Prostate Cancer Outcomes

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Community Oncology Well Suited for Advanced Cancer Patients

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Todays Updates

An Oral Ketamine Drug for Depression — Minus the Trip?

A novel oral ketamine drug shows a signal for reducing depressive symptoms with minimal dissociative effects.

Info on Risk for Prostate Cancer Spurs Decision-Making

Men who receive personalized estimates of the likelihood of raised prostate-specific antigen levels are more likely to decide to get screening than those who receive general information on pros and cons.

Fast Symptom Relief in Ulcerative Colitis: Which Rx Wins?

Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis.

Europe’s AI Reality: Practice Outpaces Policy and Reviews

Clinicians and patients are already relying on AI, while hospitals are still building the oversight to keep up.

Cognitive Benefit of Healthy Living Confirmed: LatAm-FINGERS

A culturally tailored lifestyle program improves cognition significantly more than standard health advice among older adults at risk for dementia across Latin America.

Health Issues Tied to Behaviours in Intellectual Disability

People with intellectual disabilities who have physical health problems or sensory impairments face a higher risk for challenging behaviours.

Rimegepant Effective in Treatment-Resistant Migraine

Rimegepant is safe and effective in patients with migraine not responding to multiple prior preventive therapies, a real-world study shows.

Todays Updates

An Oral Ketamine Drug for Depression — Minus the Trip?

A novel oral ketamine drug shows a signal for reducing depressive symptoms with minimal dissociative effects.

Info on Risk for Prostate Cancer Spurs Decision-Making

Men who receive personalized estimates of the likelihood of raised prostate-specific antigen levels are more likely to decide to get screening than those who receive general information on pros and cons.

Fast Symptom Relief in Ulcerative Colitis: Which Rx Wins?

Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis.

Europe’s AI Reality: Practice Outpaces Policy and Reviews

Clinicians and patients are already relying on AI, while hospitals are still building the oversight to keep up.

Cognitive Benefit of Healthy Living Confirmed: LatAm-FINGERS

A culturally tailored lifestyle program improves cognition significantly more than standard health advice among older adults at risk for dementia across Latin America.

Health Issues Tied to Behaviours in Intellectual Disability

People with intellectual disabilities who have physical health problems or sensory impairments face a higher risk for challenging behaviours.

Rimegepant Effective in Treatment-Resistant Migraine

Rimegepant is safe and effective in patients with migraine not responding to multiple prior preventive therapies, a real-world study shows.

Latest News

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

News All Time

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

New Immune Therapy Boosts Disease Control in Prostate Cancer

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

Is There a Role for Stimulants in Beating Cancer Fatigue?

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Combination Treatment May Improve Multiple Myeloma Outcomes

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

Inside the Major Findings From the NHS-Galleri Trial

The largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.

The Growing Role of AI in Cancer Treatment

Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

Pain that interferes with daily functioning is associated with higher odds of frailty and its progression in adult survivors of childhood cancer.

PSA Screening May Modestly Curb Prostate Cancer Deaths

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Capivasertib Wins Metastatic Prostate Cancer Approval

The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Recommended News For You

FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor

Adjuvant Radiation Boosts High-Risk Bladder Cancer Control

Less Mental Decline With Darolutamide vs Enzalutamide in PC

Radioligand Therapy Set to Transform Oncology Care

Measurable Residual Disease Predicts Real-World AML Relapse

Breast cancer patients' arms swell less after an effective lymph node transfer.

A specific drug combination is being tested in a clinical trial for the deadly brain cancer glioblastoma.

Recommended Articles For You

Innovative Strategies in Prostate Cancer Management: From Surveillance to Systemic Therapies 

Early Recognition of Immune-Related Adverse Events During Cancer Therapy 

Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies 

Unlocking the Potential of Leukemia Treatment: A New Hope for Patients 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Similar survival seen with simple versus radical hysterectomy for cervical cancer

2.

La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.

3.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

4.

Alone for 500 Days, but Never Lonely: The Introvert's Dream.

5.

Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.

1.

Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways

2.

Mapping Gene Expression in Tumors: The Emerging Role of Spatial Transcriptomics

3.

Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning 

4.

Transfusing the Future: Exploring the Possibilities of Blood Transfusions

5.

A New Hope: How Procarbazine is Revolutionizing Cancer Treatment

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

3.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

4.

Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment

5.

Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot